Medical Condition News

RSS

High dose aspirin effective for treatment of severe headache and migraine

An inexpensive, hundred-year-old therapy for pain - aspirin - is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center. Study participants were administered aspirin through an IV and 25 percent of the time they reported a significant reduction in pain - three points on the 10-point pain scale.

22 Sep 2010

Bioconnect's Optiflow Vascular Anastomotic System granted CE mark approval

Bioconnect Systems, Inc. today announced CE mark approval for the Optiflow™ Vascular Anastomotic System. The Optiflow™ enhances a surgeon's ability to create precise vascular connections. The initial indication is the creation of an arteriovenous fistula needed for vascular access in hemodialysis patients.

21 Sep 2010

Biodegradable polymers represent future of stent design

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

21 Sep 2010

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.

21 Sep 2010

Incidence of hockey-related injuries among children doubles

The incidence of hockey-related injuries among children aged 9 to 14 leading to emergency department visits more than doubled between 1990 and 2006, according to a new nationwide study.

21 Sep 2010

HHS awards ICF International $11.7M contract under CDC task order

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a new $11.7 million contract by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC). The contract has a term of three years. The contract is awarded under a CDC National Center for Birth Defects and Developmental Disabilities ID/IQ task order.

21 Sep 2010

EffRx, Nycomed announce European filing for EX101 marketing approval

EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.

21 Sep 2010

Five Prime Therapeutics receives patent for lead oncology product

Five Prime Therapeutics, Inc. today announced it has been issued two patents, U.S. Patent No. 7,678,890 and European Patent No.1910542B1, with claims covering various engineered Fibroblast Growth Factor Receptor ("FGFR") fusion proteins, including composition of matter claims for its lead oncology product, FP-1039.

21 Sep 2010

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that Health Canada has issued a medical device license for its automated IgX PLEX Celiac(TM) microarray test kit that runs on the Company's automated SQiDworks(TM) platform. The license allows the Company to market and sell the IgX PLEX Celiac product in Canada.

21 Sep 2010

New genes associated with osteoarthritis progression

Scientists from University of North Carolina at Chapel Hill School of Medicine and Interleukin Genetics, Inc. announced today findings from a large clinical study to evaluate the role played by genetic factors in the worsening of osteoarthritis.

21 Sep 2010

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

National survey highlights need for greater awareness on lymphoma

While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States. Survey results showed a high number of adults (86 percent) remain unaware that there are 67 different types of lymphoma - 61 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma.

21 Sep 2010

FDA approves Mylan's generic Prograf Capsules ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tacrolimus Capsules, 0.5 mg, 1 mg and 5 mg, the generic version of Astellas' Prograf® Capsules, a treatment to prevent rejection in people who have received certain organ transplants.

21 Sep 2010

Project Blue Sky helps cancer patients to feel good

blue sky scrubs are making cancer patients feel good about themselves. Through Project Blue Sky, blue sky scrubs is able to provide patients with a fashion forward way to cover the most outward sign of sickness, hair loss.

21 Sep 2010

ADI releases World Alzheimer Report 2010

The World Alzheimer Report 2010 was released today to mark World Alzheimer's Day and heighten awareness of the global economic impact of Alzheimer's disease and related dementias.

21 Sep 2010

immatics raises EUR53.8million in Series C financing round

immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics' existing pipeline of advanced therapeutic cancer vaccine candidates.

21 Sep 2010

New MTWA technology is integrated in Quinton Q-Stress cardiac stress systems

Cambridge Heart, Inc., a developer of noninvasive diagnostic tests for cardiac disease, today announced the launch of its Microvolt T-Wave Alternans (MTWA) technology as an integrated part of industry-leading cardiac stress test systems manufactured and distributed by Cardiac Science Corporation. The MTWA technology, which can predict a patient's risk of sudden cardiac arrest (SCA), is now being offered to new and existing users of Cardiac Science's Quinton Q-Stress cardiac stress systems.

21 Sep 2010

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

The University of Maryland School of Pharmacy has received a prestigious $3.7 million grant to develop a drug to treat cocaine addiction based on an active ingredient found in some Chinese prescription medicines.

21 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010